S.A. Mason LLC Buys 451 Shares of Zoetis Inc. (NYSE:ZTS)


Share on StockTwits

S.A. Mason LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 11.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,389 shares of the company’s stock after buying an additional 451 shares during the quarter. S.A. Mason LLC’s holdings in Zoetis were worth $691,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. IHT Wealth Management LLC raised its holdings in shares of Zoetis by 4.6% in the 3rd quarter. IHT Wealth Management LLC now owns 1,533 shares of the company’s stock valued at $254,000 after purchasing an additional 68 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at about $1,151,000. Jeppson Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at about $25,000. Paces Ferry Wealth Advisors LLC bought a new stake in shares of Zoetis in the 3rd quarter valued at about $65,000. Finally, Advisor Partners LLC raised its holdings in shares of Zoetis by 0.7% in the 3rd quarter. Advisor Partners LLC now owns 16,275 shares of the company’s stock valued at $2,691,000 after purchasing an additional 109 shares in the last quarter. Institutional investors own 92.50% of the company’s stock.

Several research firms have recently commented on ZTS. Bank of America upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 price target for the company in a report on Monday, March 15th. Raymond James upgraded shares of Zoetis from a “market perform” rating to an “outperform” rating and set a $166.00 price target for the company in a report on Monday, March 15th. Finally, Credit Suisse Group lifted their price objective on shares of Zoetis from $197.00 to $203.00 in a research report on Wednesday, February 17th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and an average target price of $170.08.

NYSE:ZTS opened at $169.07 on Friday. The company has a market cap of $80.31 billion, a PE ratio of 50.17, a P/E/G ratio of 4.35 and a beta of 0.71. Zoetis Inc. has a twelve month low of $121.50 and a twelve month high of $176.64. The company has a current ratio of 3.47, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41. The company’s 50 day moving average is $156.67 and its two-hundred day moving average is $160.85.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, February 16th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.05. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.73 billion. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. During the same quarter in the previous year, the firm earned $0.92 EPS. As a group, analysts expect that Zoetis Inc. will post 3.63 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 1st. Shareholders of record on Wednesday, April 21st will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Tuesday, April 20th. Zoetis’s dividend payout ratio is presently 27.47%.

In other Zoetis news, Director Robert W. Scully acquired 7,590 shares of the company’s stock in a transaction dated Friday, February 19th. The shares were acquired at an average cost of $164.68 per share, with a total value of $1,249,921.20. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Heidi C. Chen sold 11,637 shares of the company’s stock in a transaction on Wednesday, April 21st. The shares were sold at an average price of $170.14, for a total transaction of $1,979,919.18. Following the completion of the sale, the executive vice president now directly owns 36,282 shares in the company, valued at $6,173,019.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,746 shares of company stock worth $2,635,714. 0.17% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Article: What are popular green investing opportunities?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.